Drug Sponsors

Takeda renames Millennium as Takeda Oncology

Wednesday, December 10, 2014 01:10 PM

Takeda Pharmaceutical has announced its global oncology business unit, headquartered in Cambridge, Mass., now will be called Takeda Oncology. The creation of Takeda Oncology will improve the company's ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide. Takeda will sustain its long-standing entrepreneurial approach to oncology R&D, while expanding its global commercial network and resources as Takeda Oncology.

More... »


Merck to acquire Cubist Pharmaceuticals for $9.5B to expand hospital acute care pipeline

Monday, December 8, 2014 03:29 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Shying away from mega-mergers to instead focus on mid-sized drug makers that complement its product pipeline, Merck said this morning it will acquire Cubist Pharmaceuticals for $9.5 billion, including $1.1 billion in debt.

More... »

CenterWatch

As GSK restructuring cuts 900 jobs in RTP, Parexel absorbs 450 of them in new business unit

Monday, December 8, 2014 01:30 PM

By Ronald Rosenberg
CenterWatch Staff Writer

GlaxoSmithKline’s global restructuring was felt sharply in North Carolina this week as it announced plans to cut 900 jobs in Research Triangle Park (RTP), where it has 2,500 employees and contractors working in research and development.

More... »

BTG acquires PneumRx for up to $475 million

Thursday, December 4, 2014 12:34 PM

London-based BTG will acquire PneumRx, a Mountain View, Calif.-based interventional pulmonology company in a deal worth up to $475 million, based on an initial consideration of $230 million and up to $245 million in performance-related milestone payments. BTG is an international specialist healthcare company active in interventional medicine and specialty pharmaceuticals. 

More... »

Otsuka to acquire Avanir for $3.5 billion

Tuesday, December 2, 2014 11:32 AM

Tokyo-based Otsuka Pharmaceutical will acquire Avanir Pharmaceuticals of Aliso Viejo, Calif., for $17 per share in cash, for a total value of approximately $3.5 billion.

More... »

BioMarin to acquire Prosensa for $680M

Tuesday, November 25, 2014 08:30 AM

BioMarin Pharmaceutical, based in San Rafael, Calif., will acquire Prosensa for $17.75 per share, for a total up-front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016, and Europe no later than Feb. 15, 2017, respectively.

More... »

Report: 80% of pharma outsource some of their government reimbursement budgets

Monday, November 24, 2014 02:53 PM

Eighty percent of surveyed pharma companies outsource some portion of their government reimbursement budgets, including third-party audits that can help companies remain compliant to changing industry guidelines, according to Cutting Edge Information, a Research Triangle Park, N.C.-based pharmaceutical business intelligence provider.

More... »

SEC suspends trading in companies touting Ebola-related prevention/treatment operations

Monday, November 24, 2014 02:49 PM

The Securities and Exchange Commission has suspended trading in four companies that claim to be developing products or services in response to the Ebola outbreak, citing a lack of publicly available information about the companies' operations.

More... »

AstraZeneca to expand its Maryland biologics manufacturing center, add 300 jobs

Monday, November 24, 2014 02:44 PM

AstraZeneca plans to expand its biologics manufacturing center in Frederick, Md. The more than $200 million project will increase production capacity at the facility to support AZ’s maturing pipeline, and will help the company keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AZ’s overall pipeline.

More... »

Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals

Friday, November 21, 2014 11:18 AM

Apellis Pharmaceuticals, a Crestwood, Ky.-based, clinical stage immunotherapy company, will acquire Potentia Pharmaceuticals, an early stage biotechnology company also located in Crestwood. Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration (dry AMD).

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs